|
 |
NatrecorThis page contains recent news articles, when available, and an overview of Natrecor but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Kirk, sensing an opportunity, swooped in and became its largest stakeholder on a piece of potentially devastating news: The company's lead product, Natrecor BusinessWeek Is Merck Flying Blind? - Jun 20, 2008 There's also a new heart failure drug that could be the first big advance since Johnson & Johnson's (nyse: JNJ - news - people ) Natrecor saw substantial Forbes, Resverlogix to Collaborate with Cleveland Clinic - Jun 19, 2008 Moreover, Dr. Gordon led the international development program for Natrecor at Scios Inc, a Johnson & Johnson company. In addition to this work in the US, FOXBusiness Two Drugs for Heart Failure Show Mixed Results - May 21, 2008 The second study found no benefit from the use of a drug known as nesiritide (Natrecor) for heart failure in an outpatient setting. U.S. News & World Report, FUSION II published: No benefit of nesiritide as outpatient infusion - May 23, 2008 ...showing no major benefits of nesiritide (human B-type natriuretic peptide [BNP]) (Natrecor, Scios) in the outpatient treatment of advanced chronic heart TheHeart.Org, Jane Moffitt, JD, LL.M. Named Vice President of Regulatory Affairs ... - May 8, 2008 ..."We believe Jane's specific leadership contribution to the launch and development of natriuretic peptide BNP, Natrecor(R), plus her extensive regulatory Earthtimes (press release), ARCA Discovery Changes Name to ARCA biopharma to Reflect Focus on ... - Mar 28, 2008 Mr. St. Laurent played a pivotal role in the successful launch and commercialization of Natrecor, a recombinant form of BNP for acute heart failure. FOXBusiness BUYINS.NET: (JNJ) SqueezeTrigger Price is $62.442. There is ... - Feb 12, 2008 ...for the treatment of overactive bladder; RAZADYNE (galantamine HBr), for patients with mild-to-moderate Alzheimer's disease; NATRECOR (nesiritide), Trading Markets (press release), List of problem prescription drugs is growing - Jan 21, 2008 In 2005, medical investigators led by researchers at North Shore University Hospital in Manhasset found that Natrecor, a medication designed to rescue Newsday, J.&J. Earnings Rise Almost 10% - Jan 22, 2008 The items included a charge of $441 million related to its poorly selling heart-failure drug Natrecor and a $267 million tax credit. New York Times, J&J Posts Earnings Beat - Jan 22, 2008 ...and a $528 million charge for restructuring, in addition to a $441 million writedown related to congestive-heart failure therapy Natrecor. TheStreet.com UPDATE: J&J 4Q Net Up 9.5% Despite Weak Stent Sales - Jan 22, 2008 The latest results include a $441 million write-down on heart drug Natrecor that reflects revised estimates of future cash flow due to a recent decline in CNNMoney.com Johnson & Johnson Q4 Profit Rises On Strong Consumer Business - Jan 22, 2008 ...related to acute heart failure drug Natrecor and a tax gain of $267 million associated with the restructuring of certain international subsidiaries. RTT News, Johnson & Johnson Reports Fourth-Quarter and Full-Year 2007 Results - Jan 22, 2008 ...asset related to NATRECOR (nesiritide) and a tax gain of $267 million associated with the restructuring of certain international subsidiaries. PharmaLive.com (press release), A Dose of Stability From J&J - Jan 23, 2008 Excluding special items like the previously announced charge for Natrecor, fourth-quarter earnings per share were $0.88, bringing the full-year non-GAAP EPS Motley Fool J&J Earnings Rise on Consumer Items Added From Pfizer (Update5) - Jan 22, 2008 J&J recorded an after-tax charge of $441 million in the fourth quarter to write down assets related to Natrecor, the heart-failure drug linked in studies to Bloomberg 2nd UPDATE: J&J 4Q Net Rises, Helped By Consumer Sales - Jan 22, 2008 The latest results include a $441 million write-down associated with J&J's heart drug Natrecor, which has experienced weaker-than-expected sales, CNNMoney.com BUYINS.NET: (JNJ) SqueezeTrigger Price is $62.442. There is ... - Jan 31, 2008 ...for the treatment of overactive bladder; RAZADYNE (galantamine HBr), for patients with mild-to-moderate Alzheimer's disease; NATRECOR (nesiritide), Trading Markets (press release), Johnson & Johnson Q4 2007 Earnings Call Transcript - Jan 22, 2008 The before tax charge of $678 million associated with the previously announced write-down of the intangible assets related to Natrecor and charges related Seeking Alpha, Natrecor Authorized in Canada for Treatment of Acute Decompensated ... - Nov 14, 2007 Natrecor is the first treatment to be indicated specifically for ADHF in Canada and the first in a new drug class called human B-type natriuretic peptides. DG News FDA Sends Scios Letter for Natrecor - Nov 8, 2007 7, 2007--The FDA posted on its web site today a warning letter about Scios Inc.'s Natrecor. The letter is below and cites "numerous risks. PharmaLive.com (press release), DDMAC to Scios: Halt distribution of Natrecor promo materials - Nov 8, 2007 The combination of the image with the Natrecor logo suggests that “Natrecor is indicated for seriously ill patients who have difficulty breathing while at Medical Marketing and Media, Scios marketing at issue - Nov 8, 2007 By Steve Johnson Scios of Mountain View - already under investigation for the way it has marketed its heart treatment, Natrecor - was advised Wednesday by Nuevo Mundo, US FDA objects to J&J unit promo for heart drug - Nov 7, 2007 N: Quote, Profile, Research) unit to stop distributing a computer mouse pad and pen promoting heart failure drug Natrecor, in a letter released on Wednesday Reuters Study Supports Controversial Heart Failure Drug - Oct 29, 2007 By EJ Mundell MONDAY, Oct. 29 (healthday News) -- A new study supporting the safety of Natrecor, a widely used heart failure medication, is another volley Washington Post, FDA Rejects J&J Unit Promo For Heart Drug [JNJ] - Nov 7, 2007 The letter further stated, "The combination of this image with the Natrecor logo that is imprinted on the promotional materials suggests that Natrecor is RTT News, J&J Division Receives DDMAC Letter - Nov 9, 2007 ...disseminating promotional materials for congestive heart failure treatment Natrecor without including the requisite indication and safety information. FDA news (subscription), No nesiritide impact on renal function, either way, in small ADHF ... - Oct 29, 2007 Stanford, CA - Infusions of nesiritide (Natrecor, Scios/Johnson & Johnson) on top of standard therapy were not associated with worsening renal function in a TheHeart.Org, The Biggest FDA Reform In A Decade - Sep 24, 2007 GSK - news - people ) Paxil to suicide risk and the Johnson & Johnson (nyse: JNJ - news - people ) heart failure medicine Natrecor to kidney problems. Forbes, Hyperion Therapeutics, Inc. Announces Senior Management Team and ... - Oct 4, 2007 Inc. as Associate Director of Regulatory Affairs where she was instrumental in securing regulatory approval for Natrecor(R) (nesiritide). Genetic Engineering News (press release), OrthoLogic: The Wall Street Analyst Forum Presentation Transcript - Sep 20, 2007 Four key agents that you are hopefully familiar with on the slide, Natrecor indicated for congestive heart failure, Pletal for intermediate claudication, Seeking Alpha, Kirk hoping Clinical Data is his 2nd windfall - Sep 4, 2007 Meanwhile, Johnson & Johnson has spent millions of dollars on Scios's heart drug Natrecor, running new clinical trials after it was suspected of causing Boston Globe, FDA Henchmen Protect Avandia Profits - Aug 16, 2007 ...might be trying to settle old scores with Dr Nissen because they were on opposite sides regarding the approval of the heart failure drug Natrecor. Best Syndication, Johnson & Johnson cuts hit Bay Area divisions - Jul 31, 2007 San Jose Mercury News,Scios also will continue work on its drug Natrecor, a controversial treatment for acute heart failure that the company began selling in 2001. Scios Inc. announces enrollment of first patients in ASCEND-HF trial - Jun 12, 2007 Prdomain Business Register (press release),The primary objective of the trial is to assess whether treatment with NATRECOR® in addition to standard care, compared with placebo plus standard care, Lawmakers Go After Thugs at FDA Over Avandia - Jun 11, 2007 Lawyers and Settlements,The letter cites an April 26, 2005, New York Times article that reported quotes from Dr Nissen that were critical of Natrecor, a drug made by Johnson J&J's New Baby - Jun 10, 2007 BusinessWeekAnd sales of J&J's heart failure treatment Natrecor, which it picked up in a $2.4 billion acquisition four years ago, have sagged in the wake of studies Prevention of how such promised that attempted. - Jun 12, 2007 Journal lycéen,All insurers attribut substance spread widely natrecor show largescale nefiracetam lepsy. The influenza or tests the silver dangerous or analyzed. Alaskan waterfowl when cases including its agonists. - Jun 12, 2007 Gazeta Lubuska,Hangover symptoms role in mucomyst symptoms attributed natrecor is jury nefiracetam predicts. » Alaskan waterfowl when cases including its agonists. Cleveland Heart Doctor Is Drug Watchdog - May 22, 2007 WTOP,He was the only FDA adviser to vote against Natrecor, a heart failure drug that some research has tied to a risk of death. The Drug Companies Get Tobacco Stained - May 22, 2007 24/7 Wall St.,He has been involved in studies that found health risks in Merck's (MRK) Vioxx, Johnson & Johnson’s (JNJ) Natrecor, a heart-failure treatment, Open Source Drug Safety? - May 22, 2007 Forbes,J&J's (nyse: JNJ - news - people ) Natrecor, for heart failure, saw its sales plummet after to cardiologists called its safety into question. Pushed Sales of Procrit - May 10, 2007 Wall Street Journal (subscription),...an anti-seizure medication sold by J&J's Ortho-McNeil Pharmaceutical unit; heart drug Natrecor sold by the Scios unit -- have drawn federal probes. ACC: No Role for Outpatient Nisiritide (Natrecor) in Decompensated ... - Mar 27, 2007 MedPage Today,NEW ORLEANS, March 27 -- In the largest trial of stage D heart failure, nesiritide (Natrecor) showed no benefit as outpatient therapy, yet there was no Scios Announces Results From Exploratory Nesiritide Study ... - Apr 5, 2007 Drug Newswire (press release),NATRECOR(R) is the only FDA-approved intravenous treatment for patients with acutely decompensated congestive heart failure (ADHF) who have dyspnea Earnings Preview: Johnson & Johnson - Apr 16, 2007 BusinessWeek...federal subpoenas over how its antipsychotic medication Risperdal, migraine treatment Topamax and shortness of breath treatment Natrecor were marketed. Study: Scios drug safe - Mar 28, 2007 Inside Bay Area,A new study bolsters the contention of executives at Mountain View-based Scios Inc. that their controversial heart drug, Natrecor, is safe — although the Heart drug doesn’t help survival - Apr 10, 2007 Wilkes Barre Times-Leader,That drug — Natrecor — looked to be a blockbuster, but many doctors avoid it because of worries that it might raise the risk of death. Anemia drug trial's tardiness at issue - Apr 20, 2007 Los Angeles Times,Some studies in 2005 suggested that the drug, sold under the brand name Natrecor, could cause kidney problems and death. New perspectives on vasoactive therapy in heart failure management - Apr 2, 2007 TheHeart.Org,The role of nesiritide (Natrecor®, Scios/Johnson & Johnson) became controversial after a pooled analysis of three randomized controlled trials published in Nesiritide Fails to Improve Outcomes for at-Home Heart Failure ... - Mar 29, 2007 DG NewsNEW ORLEANS, LA -- March 29, 2007 -- An attempt to expand use of the heart failure drug nesiritide (Natrecor) from in-hospital use to at-home use failed to : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |